Deck Bio Launches Multi-Target T Cell Engager Platform for Solid Tumors

Preclinical data on lead program DBXO-1 to be presented at AACR 2026

Apr. 10, 2026 at 3:39am

Got story updates? Submit your updates here. ›

A highly structured abstract painting in earthy tones of green, brown, and blue, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conveying the intricate scientific concepts behind Deck Bio's T cell engager technology for solid tumor immunotherapy.Deck Bio's innovative multi-target T cell engager platform aims to unlock the full potential of immunotherapy in solid tumors, using a bold, conceptual visual to represent the complex scientific forces at play.Cambridge Today

Emerging biotechnology company Deck Bio is launching a novel multi-target T cell engager (TCE) platform designed to expand the reach of immunotherapy in solid tumors. The company's approach integrates proprietary technologies to enable precise targeting of intracellular cancer antigens, with the goal of improving safety, patient access, and durability of response. Deck Bio's lead program, DBXO-1, will be the focus of a presentation at the upcoming AACR Annual Meeting 2026.

Why it matters

While immuno-oncology therapies have transformed cancer treatment, a significant unmet need remains for broader patient populations. Current TCEs have shown limited impact on solid tumors due to tumor heterogeneity, antigen escape, and the difficulty of safely accessing intracellular targets. Deck Bio's multi-target approach aims to overcome these challenges and expand the potential of TCEs in solid tumors.

The details

Deck Bio is developing first-in-class TCEs that target tumor-exclusive peptide–major histocompatibility complex (pMHC) proteins, enabling access to a broad range of cancer-driving targets inside the cell. Unlike single-antigen TCEs, the company's candidates are designed to recognize multiple tumor-specific targets through a single engineered binder. This approach is intended to improve tumor specificity, expand patient eligibility, and reduce the risk of resistance. Deck Bio's platform integrates a stabilized T cell receptor domain (dbTv™), a T cell engaging arm (dbTCE™), and a sequence-agnostic specificity profiling platform (dbSCOPE™) to guide the design of highly selective therapies.

  • Deck Bio was founded in 2023.
  • The company has raised approximately $3.1 million in funding since its founding.
  • Preclinical data on Deck Bio's lead program, DBXO-1, will be presented at the AACR Annual Meeting 2026 on April 20, 2026.

The players

Deck Bio

A biotechnology company developing novel immunotherapies to unlock the potential of T cell engagers in solid tumors.

Jack Silberstein, Ph.D.

The founder and CEO of Deck Bio, a Stanford-trained protein engineer.

Johanna Kaufmann, Ph.D.

The Chief Scientific Officer of Deck Bio, who will be presenting the preclinical data on DBXO-1 at the AACR Annual Meeting 2026.

Got photos? Submit your photos here. ›

What they’re saying

“Deck Bio was founded to tackle fundamental challenges in targeting cancer, including the limitations of single-antigen approaches and the difficulty of safely accessing intracellular targets.”

— Jack Silberstein, Ph.D., Founder & Chief Executive Officer of Deck Bio

“Our goal is to expand the reach of T cell engagers in solid tumors, where patients continue to face significant unmet need.”

— Johanna Kaufmann, Ph.D., Chief Scientific Officer of Deck Bio

What’s next

Additional details on Deck Bio's lead program, DBXO-1, will be highlighted during the upcoming presentation at the AACR Annual Meeting 2026 on April 20, 2026.

The takeaway

Deck Bio's multi-target T cell engager platform represents a promising approach to overcoming the limitations of current immuno-oncology therapies in solid tumors, with the potential to improve safety, patient access, and durability of response for cancer patients.